Lilly to Acquire Verve Therapeutics in a $1.3 Billion Deal for Innovative Cardiovascular Gene Editing Medicines

Eli Lilly and Company has entered into a definitive agreement to acquire Verve Therapeutics, Inc. for approximately $1.3 billion, accelerating the development of potential one-dose gene editing medicines for cardiovascular disease.